Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biovie Inc (NQ: BIVI )

2.770 +0.030 (+1.09%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biovie Inc

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
BIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioVie Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioVie Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BIVI
From The Rosen Law Firm PA
Via GlobeNewswire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of BioVie, Inc. (BIVI) Investors
From Kirby McInerney LLP
Via Business Wire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioVie Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – BIVI
From The Rosen Law Firm, P.A.
Via Business Wire
BIOVIE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioVie Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
Via ACCESSWIRE
ROSEN, A LONGSTANDING LAW FIRM, Encourages BioVie Inc. Investors to Inquire About Securities Class Action Investigation – BIVI
From The Rosen Law Firm, P.A.
Via Business Wire
Dow Jumps Over 100 Points; Hormel Foods Earnings Miss Estimates
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 100 points on Wednesday. The Dow traded up 0.42% to 35,564.02 while the NASDAQ rose 0.17% to 14,305.43. The... 
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Patterson Companies, Inc. (NASDAQ: PDCO) moved lower during Wednesday’s session after the company reported worse-than-expected second-quarter financial results and lowered FY24 adjusted EPS... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Is Farfetch (FTCH) Stock Down 50% Today?
Farfetch stock is falling on Wednesday as shares of FTCH have been volatile alongside going private reports, delayed earnings and more. 
Via InvestorPlace
Crude Oil Rises 1%; Rover Group Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points on Wednesday. The Dow traded up 0.17% to 35,476.23 while the NASDAQ rose 0.35% to 14,331.13. The... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Vivos Therapeutics (VVOS) Stock Up 290% Today?
Vivos Therapeutics stock is rocketing higher on Wednesday with heavy trading of VVOS shares following approval from the FDA! 
Via InvestorPlace
Why Is BioVie (BIVI) Stock Down 63% Today?
BioVie stock is falling after its Phase 3 clinical trial of its Alzheimer’s treatment candidate failed to show statistical significance. 
Via InvestorPlace
Why Is Alzheimer's-Focused BioVie Stock Trading Lower Today?
BioVie Inc (NASDAQ: BIVI) shares are trading lower after the company released an analysis of unblinded, topline efficacy data from its Phase 3 trial of NE3107 for mild to  
Via Benzinga
Nasdaq Surges Over 100 Points; US Economy Expands Faster Than Expected
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.13% to 35,461.86 while the... 
Via Benzinga
Topics Economy Stocks
Exposures Economy US Equities
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Palo Alto Networks Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ: PANW) fell in pre-market trading after reporting first-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Thursday! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why JetBlue Airways Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian patent office for its patent application for... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Owens Corning Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. 
Via Benzinga
Why Microsoft Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Gainers ReShape Lifesciences Inc. (NASDAQ: RSLS) shares surged 62.8% to $0.3348 in pre-market trading after gaining over 6% on Tuesday. ReShape Lifesciences recently announced pricing of $3.0 million... 
Via Benzinga
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate. 
Via Talk Markets
BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation
Via ACCESSWIRE
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.